A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase i

Biochemical Pharmacology

Volumn 90, Issue 3, 2014, Pages 320-330

  Yu, Chia Chun ^a   Pan, Shiow Lin ^b   Chao, Shi Wei ^b   Liu, Shih Ping ^c   Hsu, Jui Ling ^a   Yang, Yu Chen ^d   Li, Tsia Kun ^d   Huang, Wei Jan ^b   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

DACA; DNA damage; DNA repair; Hybrid; Vorinostat

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA TOPOISOMERASE; ETOPOSIDE; HISTONE H2AX; HISTONE H3; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N HYDROXY 6 (4 CARBAMOYLACRIDINYL)HEXANAMIDE; UNCLASSIFIED DRUG; VORINOSTAT; WJ 35435;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; COMET ASSAY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION;

DACA; DNA DAMAGE; DNA REPAIR; HYBRID; VORINOSTAT;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE, NUDE; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903902541     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.06.001     Document Type: Article

References (53)

1. L. Ellis, P.W. Atadja, and R.W. Johnstone Epigenetics in cancer: targeting chromatin modifications Mol Cancer Ther 8 2009 1409 1420
2. B.M. Turner Histone acetylation and an epigenetic code BioEssays 22 2000 836 845
3. L. Verdone, M. Caserta, and E. Di Mauro Role of histone acetylation in the control of gene expression Biochem Cell Biol 83 2005 344 353 (Pubitemid 41297202)
4. J. Li, G. Li, and W. Xu Histone deacetylase inhibitors: an attractive strategy for cancer therapy Curr Med Chem 20 2013 1858 1886
5. P. Perego, V. Zuco, L. Gatti, and F. Zunino Sensitization of tumor cells by targeting histone deacetylases Biochem Pharmacol 83 2012 987 994
6. D. Secci, S. Carradori, B. Bizzarri, A. Bolasco, P. Ballario, and Z. Patramani et al. Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors Bioorg Med Chem 22 2014 1680 1689
7. S. Grant, C. Easley, P. Kirkpatrick, and Vorinostat Nat Rev Drug Discov 6 2007 21 22
8. H.J. Kim, and S.C. Bae Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs Am J Transl Res 3 2011 166 179
9. M. Jakopovic, A. Thomas, S. Balasubramaniam, D. Schrump, G. Giaccone, and S.E. Bates Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy Front Oncol 3 2013 261
10. S. Salerno, F. Da Settimo, S. Taliani, F. Simorini, C. La Motta, and G. Fornaciari et al. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs Curr Med Chem 17 2010 4270 4290
11. S. Castelli, A. Coletta, I. D'Annessa, P. Fiorani, C. Tesauro, and A. Desideri Interaction between natural compounds and human topoisomerase I Biol Chem 393 2012 1327 1340
12. S.J. Froelich-Ammon, and N. Osheroff Topoisomerase poisons: harnessing the dark side of enzyme mechanism J Biol Chem 270 1995 21429 21432
13. B. Fischer, and A. Arcaro Current status of clinical trials for small cell lung cancer Rev Recent Clin Trials 3 2008 40 61 (Pubitemid 351267025)
14. M. Alagoz, D.C. Gilbert, S. El-Khamisy, and A.J. Chalmers DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets Curr Med Chem 19 2012 3874 3885
15. V. Goler-Baron, and Y.G. Assaraf Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance PLoS One 6 2011 e16007
16. M.C. Chen, C.H. Chen, H.C. Chuang, S.K. Kulp, C.M. Teng, and C.S. Chen Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells Hepatology 53 2011 148 159
17. W.J. Huang, Y.A. Tang, M.Y. Chen, Y.J. Wang, F.H. Hu, and T.W. Wang et al. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies Cancer Lett 346 2014 84 93
18. J. Gray, C.L. Cubitt, S. Zhang, and A. Chiappori Combination of HDAC and topoisomerase inhibitors in small cell lung cancer Cancer Biol Ther 13 2012 614 622
19. G.J. Atwell, G.W. Rewcastle, B.C. Baguley, and W.A. Denny Potential antitumour activity agents. In vivo solid tumour activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide J Med Chem 30 1987 664 669 (Pubitemid 17065201)
20. J.H. Guh, T.L. Hwang, F.N. Ko, S.C. Chueh, M.K. Lai, and C.M. Teng Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor Mol Pharmacol 53 1998 467 474
21. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica et al. New colorimetric cytotoxicity assay for anticancer-drug screening J Nat Cancer Inst 82 1990 1107 1112 (Pubitemid 20213250)
22. D. Wegener, F. Wirsching, D. Riester, and A. Schwienhorst A fluorogenic histone deacetylase assay well suited for high-throughput activity screening Chem Biol 10 2003 61 68 (Pubitemid 36154475)
23. C.R. Lee, J.N. Chun, S.Y. Kim, S. Park, S.H. Kim, and E.J. Park et al. Cyclosporin A suppresses prostate cancer cell growth through CaMKKβ/AMPK-mediated inhibition of mTORC1 signaling Biochem Pharmacol 84 2012 425 431
24. A. Laurenzana, M. Balliu, C. Cellai, M.N. Romanelli, and F. Paoletti Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells PLoS One 8 2013 e58267
25. T. Chen, P.A. Stephens, F.K. Middleton, and N.J. Curtin Targeting the S and G2 checkpoint to treat cancer Drug Discovery Today 17 2012 194 202
26. P.J. Hurley, and F. Bunz ATM and ATR: components of an integrated circuit Cell Cycle 6 2007 414 417 (Pubitemid 46393443)
27. M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323 (Pubitemid 39551659)
28. A. Sancar, L.A. Lindsey-Boltz, K. Unsal-Kaçmaz, and S. Linn Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu Rev Biochem 73 2004 39 85 (Pubitemid 39050363)
29. L. Zhao, M.G. Wientjes, and J.L. Au Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses Clin Cancer Res 10 2004 7994 8004 (Pubitemid 39587541)
30. J. Jiang, A. Thyagarajan-Sahu, V. Krchňák, A. Jedinak, G.E. Sandusky, and D. Sliva NAHA a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo PLoS One 7 2012 e34283
31. Y. Zhang, H. Fang, J. Feng, Y. Jia, X. Wang, and W. Xu Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities J Med Chem 54 2011 5532 5539
32. M.I. Rodríguez-Franco, M.I. Fernández-Bachiller, C. Pérez, B. Hernández-Ledesma, and B. Bartolomé Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesteraseinhibitory and antioxidant properties J Med Chem 49 2006 459 462 (Pubitemid 43157478)
33. M. Chattopadhyay, R. Kodela, K.R. Olson, and K. Kashfi NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model Biochem Biophys Res Commun 419 2012 523 528
34. K. Halkidou, L. Gaughan, S. Cook, H.Y. Leung, D.E. Neal, and C.N. Robson Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer Prostate 59 2004 177 189 (Pubitemid 38481229)
35. A.J. Wilson, D.S. Byun, N. Popova, L.B. Murray, K. L'Italien, and Y. Sowa et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J Biol Chem 281 2006 13548 13558 (Pubitemid 43855268)
36. J.H. Choi, H.J. Kwon, B.I. Yoon, J.H. Kim, S.U. Han, and H.J. Joo et al. Expression profile of histone deacetylase 1 in gastric cancer tissues Jpn J Cancer Res 92 2001 1300 1304 (Pubitemid 34036893)
37. L. Gaughan, I.R. Logan, S. Cook, D.E. Neal, and C.N. Robson Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor J Biol Chem 277 2002 25904 25913 (Pubitemid 34967070)
38. H. Kawai, H. Li, S. Avraham, S. Jiang, and H.K. Avraham Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha Int J Cancer 107 2003 353 358 (Pubitemid 37266453)
39. G. Lagger, D. O'Carroll, M. Rembold, H. Khier, J. Tischler, and G. Weitzer et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression EMBO J 21 2002 2672 2681 (Pubitemid 34619383)
40. M. Fournel, M.C. Trachy-Bourget, P.T. Yan, A. Kalita, C. Bonfils, and C. Beaulieu et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors Cancer Res 62 2002 4325 4330 (Pubitemid 34827289)
41. S. Dallavalle, C. Pisano, and F. Zunino Development and therapeutic impact of HDAC6-selective inhibitors Biochem Pharmacol 84 2012 756 765
42. P.H. Yang, L. Zhang, Y.J. Zhang, J. Zhang, and W.F. Xu HDAC6: Physiological function and its selective inhibitors for cancer treatment Drug Discovery Ther 7 2013 233 242
43. Y. Choi, S.K. Park, H.M. Kim, J.S. Kang, Y.D. Yoon, and S.B. Han et al. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model Exp Mol Med 40 2008 574 581 (Pubitemid 352789098)
44. N. Kawamata, J. Chen, and H.P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 2007 2667 2673 (Pubitemid 47523191)
45. Z. Zhang, C. Hao, L. Wang, P. Liu, L. Zhao, and C. Zhu et al. Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors OncoTargets Ther 6 2013 733 740
46. B. Ladd, J.J. Ackroyd, J.K. Hicks, C.E. Canman, S.A. Flanagan, and D.S. Shewach Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity DNA Repair (Amst) 12 2013 1114 1121
47. V. Costanzo, D. Shechter, P.J. Lupardus, K.A. Cimprich, M. Gottesman, and J. Gautier An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication Mol Cell 11 2003 203 213 (Pubitemid 36126601)
48. M. Lopes, C. Cotta-Ramusino, A. Pellicioli, G. Liberi, P. Plevani, and M. Muzi-Falconi et al. The DNA replication checkpoint response stabilizes stalled replication forks Nature 412 2001 557 561 (Pubitemid 32743836)
49. J. Smith, L.M. Tho, N. Xu, and D.A. Gillespie The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer Adv Cancer Res 108 2010 73 112
50. J.M. Furgason, and M. Bahassi el Targeting DNA repair mechanisms in cancer Pharmacol Ther 137 2013 298 308
51. L. Liu, J.H. Choi, H. Yim, J.S. Choi, B.D. Park, and S.J. Cho et al. ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induced S-phase arrest of HeLa cells Int J Biochem Cell Biol 41 2009 1410 1420
52. P.C. De Witt Hamer, S.E. Mir, D. Noske, C.J. Van Noorden, and T. Würdinger WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe Clin Cancer Res 17 2011 4200 4207
53. R. Sakasai, H. Teraoka, and R.S. Tibbetts Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin DNA Repair (Amst) 9 2010 76 82